

Adalimumab
Statut de médicament essentiel
Description générale

INN
Adalimumab
Codes ATC
[L04AB04](#)
Type de médicament
Biological agent
Historique des statuts LME
Ajouté pour la première fois en 2019 ([TRS 1021](#)) pour [Rheumatoid arthritis](#)
Ajouté en 2019 ([TRS 1021](#)) pour [Axial spondyloarthritis](#)
Ajouté en 2019 ([TRS 1021](#)) pour [Juvenile idiopathic arthritis](#)
Ajouté en 2019 ([TRS 1021](#)) pour [Crohn disease site](#)
Ajouté en 2025 ([TRS 1064](#)) pour [Psoriasis of unspecified type](#)

Wikipédia

[Adalimumab](#)

DrugBank

[Adalimumab](#)

Recommandations

Section

Immunomodulators for non-malignant disease

- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

Indications

[Rheumatoid arthritis](#) [Axial spondyloarthritis](#) [Crohn disease site](#)

Section

Medicines for juvenile joint diseases

- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

Indications

[Juvenile idiopathic arthritis](#)

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Parenteral > General injections > SC: 10 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.; 80 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.

Indications

[Psoriasis of unspecified type](#)